(Cancer of Unknown Primary) Is Opdivo Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- December 13, 2021
- 1 min read
On November 26, 2021, Dr. Junko Tanizaki and colleagues from Kindai University Faculty of Medicine published results in Annals of Oncology from the NivoCUP Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody Opdivo (nivolumab) in cancer of unknown primary (CUP) patients.
This multi-center, single-arm Phase 2 trial administered Opdivo (240 mg every 2 weeks, up to 52 cycles) to CUP patients (N=56), with objective response rate (ORR) as the primary endpoint. Of these patients, 45 had received one prior line of therapy.
The trial was initiated because CUP carries a poor prognosis, and immune checkpoint inhibitors have demonstrated efficacy across multiple cancer types. The study aimed to evaluate the therapeutic value of nivolumab in this difficult-to-treat population.
Results (in patients with prior treatment, N=45):
- Objective response rate (ORR): 22.2%
- Median progression-free survival (PFS): 4.0 months
- Median overall survival (OS): 15.9 months
Safety: The safety profile was consistent with existing nivolumab clinical trial data. No treatment-related deaths were reported.
Conclusion: Based on the NivoCUP trial results, Dr. Tanizaki and colleagues concluded that Opdivo demonstrated promising anti-tumor activity in CUP patients, potentially representing a new treatment option for this population.
Source: https://www.annalsofoncology.org/article/S0923-7534(21)04824-9/fulltext
-
Immunotherapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4